Single high-dose melphalan/autologous transplantation (HDM/ASCT) was non-inferior to tandem HDM/ASCT in patients with multiple myeloma, according to a study published in the British Journal of Haematology.1

Investigators sought to determine whether single (arm A) versus tandem (arm B ) HDM/ASCT was non-inferior in terms of 2-year event-free survival (EFS) in patients with newly diagnosed multiple myeloma in this prospective, randomized phase 3 trial.

A total of 358 evaluable patients were included in the intention-to-treat population; 177 patients were in arm A and 181 were in arm B.

Continue Reading

Results showed that after a median follow-up of more than 11 years, non-inferiority was demonstrated using the planned non-inferior threshold of 15% of the 2-year EFS rate. No differences were found in the EFS or overall survival rates (P = .53; P = .33, respectively).

This was consistent with the results of a per-protocol analysis, which included patients who received the intervention (single/tandem HDM/ASCT; 156 patients/93 patients) and those who did not receive a second HDM/ASCT due to medical reasons (12%). A total of 26% of patients in the tandem arm refused a second HDM/ASCT due to non-medical reasons.

RELATED: Single-agent Cabozantinib Lacks Activity in R/R Myeloma

The rates of complete responses increased from first to second HDM/ASCT  in both the intention-to-treat and per-protocol set of the tandem arm (both P = .04). Ten-year overall survival for the entire intention-to-treat population was 34% (95% CI, 29 – 40). Overall survival after first relapse was significantly shortened in the tandem arm (P = .04).

Reference

  1. Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial [published online ahead of print March 17, 2016]. Br J Haematol. doi: 10.1111/bjh.13994.

Singlehigh-dose melphalan/autologous transplantation (HDM/ASCT) was non-inferior totandem HDM/ASCT in patients with multiple myeloma, according to a studypublished in the British Journal ofHaematology.1

 

Investigatorssought to determine whether single (arm A) versus tandem (arm B ) HDM/ASCT wasnon-inferior in terms of 2-year event-free survival (EFS) in patients with newlydiagnosed multiple myeloma in this prospective, randomized phase 3 trial.

 

A totalof 358 evaluable patients were included in the intention-to-treat population;177 patients were in arm A and 181 were in arm B.

 

Resultsshowed that after a median follow-up of more than 11 years, non-inferiority wasdemonstrated using the planned non-inferior threshold of 15% of the 2-year EFSrate. No differences were found in the EFS or overall survival rates (P = .53; P = .33, respectively).

 

Thiswas consistent with the results of a per-protocol analysis, which includedpatients who received the intervention (single/tandem HDM/ASCT; 156 patients/93patients) and those who did not receive a second HDM/ASCT due to medicalreasons (12%). A total of 26% of patients in the tandem arm refused a secondHDM/ASCT due to non-medical reasons.

 

Therates of complete responses increased from first to second HDM/ASCT  in both the intention-to-treat andper-protocol set of the tandem arm (both P= .04). Ten-year overall survival for the entire intention-to-treatpopulation was 34% (95% CI, 29 – 40). Overall survival after first relapse wassignificantly shortened in the tandem arm (P= .04).

 

Reference

1. Mai EK, Benner A, Bertsch U, et al.

 

Single versus tandem high-dose melphalanfollowed by autologous blood stem cell transplantation in multiple myeloma:long-term results from the phase III GMMG-HD2 trial [published online ahead ofprint March 17, 2016]. Br J Haematol.doi: 10.1111/bjh.13994

Topics:

Hematologic Cancers Multiple Myeloma